Fig. 1From: Potential and pitfalls of 89Zr-immuno-PET to assess target status: 89Zr-trastuzumab as an exampleTumor uptake of mAbs. Tumor volume fractions (a). Distribution of mAb after administration (b). Equilibrium distribution of mAb in a tumor without target expression (c). Distribution of mAb in a HER2-positive tumor (d). Target can be synthesized and degraded, mAb-target complexes can be internalizedBack to article page